investors

Press Releases
Date Title and Summary View
May 12, 2016 LOS ANGELES, May 12, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter of 2016.  Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: "We continue to make progress in all aspects of implementing our ICT-107 registration trial in...
May 6, 2016 LOS ANGELES, May 6, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company has received approval from regulatory authorities in Canada, the United Kingdom and the Netherlands to initiate the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. Patient ...
May 4, 2016 LOS ANGELES, May 4, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2016 financial results on Thursday, May 12, 2016. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the first quarter 2016 financial resu...
March 30, 2016 LOS ANGELES, March 30, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for 2015.  Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: "We made important progress in advancing the company in 2015.  In particular, we designed and began executing wha...
March 29, 2016 LOS ANGELES, March 29, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for 2015 on Wednesday, March 30, 2016. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the 2015 financial results and provide a ...
March 7, 2016 LOS ANGELES, March 7, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 at 8:30 am PT, at the Ritz-Carlton Hotel...
February 16, 2016 LOS ANGELES, Feb. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors (TCRs) developed in the laboratory of Prof. Mark Davi...
February 1, 2016 LOS ANGELES, Feb. 1, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 18th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 8, 2016, at the Waldorf Astoria Hotel in...
January 27, 2016 LOS ANGELES, Jan. 27, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore. ...
December 14, 2015 LOS ANGELES, Dec. 14, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newl...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase
Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved